Sign Up to like & get
recommendations!
0
Published in 2019 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/1756286419843450
Abstract: Background: Dimethyl fumarate (DMF) is licensed for treatment of relapsing–remitting multiple sclerosis (RRMS). DMF can induce lymphopenia, which is assumed to increase the risk for opportunistic infections like progressive multifocal leukoencephalopathy. Our goal for this…
read more here.
Keywords:
time course;
course lymphocyte;
grade lymphopenia;
repopulation ... See more keywords